Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis

被引：0
|
作者：
Keystone, Edward [1 ]
van Vollenhoven, Ronald F. [2 ]
Wilkinson, Bethanie [3 ]
Fallon, Lara [4 ]
Hwang, Lie-Ju [5 ]
Chapman, Douglass [5 ]
DeMasi, Ryan [5 ]
Lee, Eun Bong [6 ]
机构：
[1] Mt Sinai Hosp, Toronto, ON, Canada
[2] Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands
[3] Pfizer Inc, Groton, CT 06340 USA
[4] Pfizer Canada, Montreal, PQ, Canada
[5] Pfizer Inc, New York, NY USA
[6] Seoul Natl Univ, Seoul, South Korea
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1608
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Correlation of Multi-Biomarker Disease Activity Score with Clinical Disease Activity Measures for the JAK1-Selective Inhibitor Filgotinib As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients
    Genovese, Mark C.
    Galien, Rene
    Pan, Yang
    Van der Aa, Annegret
    Jamoul, Corinne
    Harrison, Pille
    Tasset, Chantal
    Goyal, Lovely
    Li, Wanying
    Tarrant, Jacqueline
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [42] Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
    Keystone, Edward C.
    Breedveld, Ferdinand C.
    Kupper, Hartmut
    Li, Yihan
    Florentinus, Stefan
    Sainsbury, Iain
    RMD OPEN, 2018, 4 (01):
  • [43] Disease Activity Score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis
    Makinen, Heidi
    Kautiainen, Hannu
    Hannonen, Pekka
    Mottonen, Timo
    Korpela, Markku
    Leirisalo-Repo, Marjatta
    Luukkainen, Reijo
    Puolakka, Kari
    Karjalainen, Anna
    Sokka, Tuulikki
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (10) : 1987 - 1991
  • [44] Patient-Reported Outcomes in Early Rheumatoid Arthritis Patients Failing to Achieve Stable Low Disease Activity: Comparing Addition of Adalimumab to Methotrexate Monotherapy with Maintenance On Adalimumab Plus Methotrexate.
    Kavanaugh, Arthur
    van Vollenhoven, Ronald F.
    Emery, Paul
    Shaw, James W.
    Cifaldi, Mary A.
    Florentinus, Stefan
    Smolen, Josef S.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S162 - S163
  • [45] INFLAMMATION DETECTED WITH MODERN SENSITIVE MRI ANALYSIS DEMONSTRATES THAT THERAPEUTIC RESPONSE AS EARLY AS ONE MONTH PREDICTS 12-MONTH RADIOGRAPHIC PROGRESSION: DATA FROM A STUDY USING TOFACITINIB AND METHOTREXATE IN METHOTREXATE-NAIVE PATIENTS WITH EARLY RA
    Conaghan, P. G.
    Bowes, M. A.
    Ostergaard, M.
    Guillard, G.
    Chapman, D.
    Stein, A.
    Andrews, J.
    Xie, Z.
    Koenig, A.
    Soma, K.
    Wilkinson, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 268 - 268
  • [46] Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate: reply
    Lee, Yvonne C.
    Cui, Jing
    Costenbader, Karen H.
    Shadick, Nancy A.
    Weinblatt, Michael E.
    Karlson, Elizabeth W.
    RHEUMATOLOGY, 2009, 48 (09) : 1177 - 1177
  • [47] Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
    van der Heijde, Desiree
    Keystone, Edward C.
    Curtis, Jeffrey R.
    Landewe, Robert B.
    Schiff, Michael H.
    Khanna, Dinesh
    Kvien, Tore K.
    Ionescu, Lucian
    Gervitz, Leon M.
    Davies, Owen R.
    Luijtens, Kristel
    Furst, Daniel E.
    JOURNAL OF RHEUMATOLOGY, 2012, 39 (07) : 1326 - 1333
  • [48] Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis.
    Burmester, Gerd
    Furst, D. E.
    Combe, B. G.
    Huizinga, T. W. J.
    Bykerk, Vivian P.
    Wong, D.
    Karyekar, C. S.
    Emery, P.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1076 - S1076
  • [49] Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate
    Luedders, Brent A.
    Johnson, Tate M.
    Sayles, Harlan
    Thiele, Geoffrey M.
    Mikuls, Ted R.
    O'Dell, James R.
    England, Bryant R.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (05) : 1058 - 1063
  • [50] A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine
    Wojciechowski, Jessica
    Wiese, Michael D.
    Proudman, Susanna M.
    Foster, David J. R.
    Upton, Richard N.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (05) : 777 - 788
12345